Biomarker Design Forschungs GmbH (BDF) is a biotech R&D company incorporated in April 2009. The staff includes all the employees of the research department of Biomedica Medizinprodukte GmbH & Co Kg (Biomedica), who have successfully developed new innovative Enzyme Linked Immunosorbent Assays (ELISA) for clinical research on diseases of bone metabolism and the cardiovascular system (human and veterinarian applications).
We focus our work on the search and the identification of new innovative biomarkers (= laboratory measurement that reflects the activity of a disease process) in cooperation with Universities, small and medium Biotech companies and with leading research centers worldwide.
The business concept of BDF is based on the above mentioned successful research activities, the scientific and commercial network established and includes selling of diagnostic concepts to commercial entities along with intellectual properties generated in the course of the research. Those concepts then will be turned into new diagnostic tools by those entities refunding BDF.
The staff of BDF has long term experience in developing ELISA technology. Several diagnostic assays have been developed and are presently sold worldwide by Biomedica (see www.bmgrp.com). Core know how of BDF includes antibody preparation, purification, labeling and stabilization of biological compounds. Developed ELISAs are validated according to the criteria defined by ICH Q2. BDF is ISO 9001:2008 certified since 2009.
Biomarker Design Forschungs GmbH
Providing new innovative tools for cutting edge clinical research